Stentys (Princeton, New Jersey), a company commercializing in Europe a Self-Apposing Stent to treat acute myocardial infarction (AMI), unveiled one-year results of the APPOSITION III clinical trial in 1,000 patients post treatment of a severe heart attack at the American College of Cardiology's Scientific (ACC; Bethesda, Maryland) Session & Expo. Read More
